Introduction

!
Endoscopic submucosal dissection (ESD) is an advanced endoscopic technique that allows complete resection of early-state lesions in the gastrointestinal tract with the aim to achieve accurate histological diagnosis and prevent tumor recurrence [1] . Initially developed for gastric tumors, the procedure has become widely used as standard of care for resection of colorectal tumors in Asian countries (notably in Japan). The main steps involved in the procedure include injecting fluid into the submucosa to elevate the tumor; cutting through surrounding mucosa to gain access into the submucosa layer; and dissecting the submucosa beneath the tumor to enhance complete resection [2] . Given the relatively burdensome maneuverability of the colon in addition to its thin wall, colorectal ESD is associated with greater technical difficulty, increase procedure time and potential high risk of perforation [3] . These concerns have led to the procedure being adopted more slowly in western countries than foregut ESD. Endoscopic mucosal resection (EMR) is the most widely used minimally invasive technique for noninvasive colorectal tumors in the western world. However, accumulating evidence suggests that with adequate training, ESD could be equally as safe as the other minimally invasive alternative in addition to offering superior efficacy and lower rate of tumor recurrence [2, 4] . Nevertheless, these reports from several clinical trials and observational studies have yielded mixed results. In order to summarize the literature and assess for potential sources of heterogeneity, we conducted a systematic review and meta-analysis of available literature on the safety and efficacy of colorectal ESD. 
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Background and study aims: Endoscopic submucosal dissection (ESD) is an advanced endoscopic technique that allows en-bloc resection of gastrointestinal tumor. We systematically review the medical literature in order to evaluate the safety and efficacy of colorectal ESD.
Patients and methods:
We performed a comprehensive literature search of MEDLINE, EMBASE, Ovid, CINAHL, and Cochrane for studies reporting on the clinical efficacy and safety profile of colorectal ESD. Results: Included in this study were 13833 tumors in 13603 patients (42 % female) who underwent colorectal ESD between 1998 and 2014. The R0 resection rate was 83 % (95 % CI, 80 -86 %) with significant between-study heterogeneity (P < 0.001) which was partly explained by difference in continent (P = 0.004), study design (P = 0.04), duration of the procedure (P = 0.009), and, marginally, by average tumor size (P = 0.09). Endoscopic en bloc and curative resection rates were 92 % (95 % CI, 90 -94 %) and 86 % (95 % CI, 80 -90 %), respectively. The rates of immediate and delayed perforation were 4.2 % (95 % CI, 3.5 -5.0 %) and 0.22 % (95 % CI, 0.11 -0.46 %), respectively, while rates of immediate and delayed major bleeding were 0.75 % (95 % CI, 0.31 -1.8 %) and 2.1 % (95 % CI, 1.6 -2.6 %). After an average postoperative follow up of 19 months, the rate of tumor recurrence was 0.04 % (95 % CI, 0.01 -0.31) among those with R0 resection and 3.6 % (95 % CI, 1.4 -8.8 %) among those without R0 resection. Overall, irrespective of the resection status, recurrence rate was 1.0 % (95 % CI, 0.42 -2.1 %). Conclusions: Our meta-analysis, the largest and most comprehensive assessment of colorectal ESD to date, showed that colorectal ESD is safe and effective for colorectal tumors and warrants consideration as first-line therapy when an expert operator is available.
Patients and methods
!
We followed the recommendations of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) during all stages of the design, implementation, and reporting of this meta-analysis (Stroup 2000) [5] .
Search strategy
We performed a comprehensive literature search of MEDLINE, EMBASE, Ovid, CINAHL, and Cochrane for studies published up to October 2014. Our search query for MEDLINE was ("endo-
. Similar search terms were adapted for the other databases (• " Table S1 ).
Study selection
One investigator (EA) screened all titles and abstracts for relevance to our study. Two investigators (EA, NK) reviewed full text of these articles and applied our predefined inclusion/exclusion criteria independently and in duplicate (• " Fig. 1 ). Hand searching of reference list of the articles was also done in order to retrieve other articles that might have been missed by our search strategy. We included all studies reporting clinical outcome(s) after colorectal ESD. Our exclusion criteria were: animal studies; case reports; commentaries or general reviews; or overlapping publications (based on study period) from the same center. However, review paper and overlapping publications from the same center were included in the initial screening for further assessment of the full-text and reference list after which, for the overlapping publications, only the most updated and comprehensive publication was retained. For the multicenter studies, we excluded all overlapping individual studies from the contributing centers if their sample size is comparable or less than that contributed to the multicenter study. Otherwise, we excluded the multicenter study if there are more updated studies from individual centers that provided more information. In the few cases where an abstract provided a more updated and comprehensive reporting of outcomes than the full-text journal article(s) from the same center, the abstract was selected for our main analysis. Articles in foreign language were translated via Google translator and, when possible, a native speaker of the foreign language was solicited to double-check the data.
Data extraction
Data from each study were extracted using a standardized data extraction sheet. These included publication information such as author name, year of publication, type of publication (e. g. abstract, journal); characteristics of study cohort such as country, name of medical center, study design, number of patients, year of data collection, demographics, setting (single/multi center); characteristics of tumor such as anatomical location, number of tumors, average tumor size, macroscopic or microscopic detail; ESD procedural details such as duration of procedure and number of failed procedure; and number of patients with clinical success and adverse outcomes.
Endpoints
We assessed both measures of efficacy and adverse outcomes associated with colorectal ESD. Our primary measure of efficacy was complete (R0) resection defined as en bloc (i. e. one-piece) resection with histologically confirmed tumor-free lateral and verti- cal margins. In addition, we evaluated endoscopic en bloc (i. e. without histological confirmation) and curative resection rate as secondary endpoints. Curative resection was defined as resections with both tumor-free lateral and vertical resection margins, minimal submucosal invasion (< 1000 μm), and with no lymphovascular invasion or poorly differentiated component. Adverse outcomes included viscus perforation, major bleeding requiring intervention, and tumor recurrence. Immediate adverse outcomes refers to those occurring within 24 hours of the procedure while delayed refers to those occurring after 24 hours of the procedure. For all endpoints, the rates were evaluated as percentage of number of tumors operated.
Statistical analysis
Proportions from each study were pooled together using logisticnormal random effect model. ) has been shown to be an inaccurate method for assessing publication bias in meta-analysis of proportion, funnel plot was constructed using study size rather than 1/SE has proposed in the literature [6, 7] . Due to huge difference in the outcome of ESD between Asian and Western countries, we performed a supplementary analysis of Asian and non-Asian studies separately.
In a sensitivity analysis, we limited our studies to full-text journal publications. The result from the sensitivity analysis was compared to that of the main analysis. Analyses were performed using STATA (Version 13; StataCorp, College Station, TX), all tests were two-sided and significance level was set at 0.05.
Results
!
Of the 1090 citations retrieved through database searching, 603 were excluded because they reported no clinical outcome after ESD procedure in human (• " Fig. 1 ). Full text review was performed on 487 studies using our predefined inclusion and exclusion criteria, after which 112 studies were retained. In order to avoid potential study overlap, we additionally excluded 8 abstracts that provided no indication of the source of data such as country, state, city, or medical center. Overall, 104 articles including 58 full-text journal article and 46 abstracts published between 2007 and 2014 were retained for data synthesis. Seventy-five of these studies were from Asia while 29 were from the Western world. A total of 13 833 tumors in 13 603 patients (42 % female) with average age 66 years (range: 25 -92 years) underwent colorectal ESD between 1998 and 2014 (• " Table S2 ). The majority of these procedures were performed in Asian countries of Japan and South Korea with only a few experiences in the western world (• " Fig. 2 ). Average tumor size was 31 mm (range: 2 mm -158 mm), and the procedure was completed in an average time of 75 min (range: 5 min -600 min).
Efficacy
R0 resection rate was reported in 60 studies across which metaanalysis yielded a pooled estimate of 83 % (95 % CI, 80 -86 %) (• " Fig. 3 ). There was significant between-study heterogeneity (P < 0.001) which was partly explained by difference in continent (P = 0.004), study design (P = 0.04), and duration of the procedure (P = 0.009). In addition, there was a trend toward decreasing R0 with increasing tumor size but this did not reach statistical significance (P = 0.09) (• " Table 3) , among retrospective studies, and decreases with increasing duration of the procedure. Assessment of funnel plot asymmetry based on egger's test also showed no significant publication bias (P = 0.57). Endoscopic en bloc and curative resection rates were reported in 86 and 14 studies, respectively. Across studies, meta-analysis yielded a pooled estimate of 92 % (95 % CI, 90 -94 %) (• " Fig. S2 ) for endoscopic en bloc resection rate and 86 % (95 % CI, 80 % -90 %) (• " Fig. S3 ) for curative resection rate, although all but one of the studies reporting curative resection were from Asia. When we performed separate analysis for Asia vs Western countries, endoscopic en bloc resection rate was 94 % (95 % CI, 92 % -95 %) and 82 % (95 % CI, 76 % -87 %) for Asian and Western countries, respectively.
Adverse outcomes
Perforation and major bleeding requiring intervention were the most common perioperative complications reported (• " CI, 4.6 % -9.4 %) and 1.2 % (95 %, 0.29 % -4.6 %) for Western countries, respectively, while rates of immediate and delayed major bleeding were 0.39 % (95 % CI, 0.11 % -1.3 %) and 1.8 % (95 % CI, 1.4 % -2.4 %) for Asia and 3.3 % (95 % CI, 1.4 % -7.6 %) and 3.9 % (95 %, 2.5 % -5.8 %) for Western countries, respectively (• " Table 3) . Table 3 ). All our estimates were comparable to those of sensitivity analysis as pre-specified (• " Table S3 ).
Discussion
!
Our meta-analysis showed that, across multiple studies in 15 countries, ESD demonstrated an excellent treatment success in patients with colorectal tumors. Perioperatively, perforation and major bleeding were the most commonly reported serious ad- (68, 85) N, number; R0, histologic en bloc resection rate 1 Potential sources of heterogeneity was assessed with metaregression. P < 0.05 indicates that the variable significantly explains part of the between study heterogeneity (i. e. an effect mofier). Differences in continent, lenth of the procedure, study design and average tumor size explains 18 %, 15 %, 8 %, and 4 % of the heterogeneity respectively. 2 Indicates variables that were cut at tertiles in order to ensure comparability of number of studies between groups.
verse outcomes but their risk is somewhat comparable to EMR [4, 8] . In addition, the risk of tumor recurrence in patients with treatment success after a moderate duration of follow up is very low. These findings provide evidence that ESD is effective and offers a reasonable safety profile across a wide range of patients. Treatment success was assessed in 3 ways: R0, endoscopic en bloc and curative resection rates. In this study, we considered R0 resection as primary endpoint. Across studies, there were excellent results based on this endpoint. However, there was significant heterogeneity in study estimates which were partly explained by four main factors: first, the estimates vary by continent. Difference in continent accounted for most of the heterogeneity with highest rates of clinical success being reported by studies from Asia. This, in a way, was expected because the procedure was developed in Asia and has been used for a long time in this part of the world allowing for the development of expert skill needed for the procedure as well as development of better techniques. On the other hand, the acceptance rate of the procedure had been low in other parts of the world. Second, lower rates of treatment success were reported in the prospective studies as compared to retrospective studies. However, only a few of the studies were prospective and most of these were from Europe, which further underscores the lower rates of treatment success in countries outside Asia. Third, rates of treatment success increase with decreasing length of the procedure. Because length of the procedure is expected to correlate with level of expertise and size of tumor, we presume this is an indicator of higher rates with better expertise/years of experience and smaller tumor size. This notion is further supported by difference in estimates by tumor size, the fourth sources of heterogeneity in our analysis, although this was only marginally significant. The relatively high risk of adverse outcome associated with the procedure had been one of the factors against the acceptability of the procedure in western countries [3] . Intraoperatively, perforation was the most common serious adverse outcome. However, most of the perforations were successfully sealed with endoscopic clips with only large ones requiring surgical intervention. More than 24 hours after the procedure, major bleeding becomes the most common serious adverse event. These cases of delayed bleeding often require endoscopic re-exploration. Although the incidence of delayed perforation is very low, it is a more serious adverse event because these usually require surgery for peritonitis [9] . The relatively low risk of recurrence has been the attractive feature of ESD. After a moderate follow up, tumor recurrence was present in only 1 in 100 tumors after the procedure, and this rate was majorly influenced by those without R0 resection i. e. patients with positive lateral or vertical tumor margins. In patients with R0 resection, the risk of recurrence is very negligible: 4 in 10 000 tumors. Overall, rates of adverse events were generally better in Asia compared to the Western world. N, number; R0, histologically-confirmed en bloc resection 1 The rates are calculated as a percentage of the total number of tumors operated. 2 Immediate refers to adverse outcomes occurring within 24 hours of the procedure. 3 Delayed refers to adverse outcome occurring 24 hours after the procedure. 4 Average follow-up was~19 months for assessment of recurrence among tumors with and without R0; and~23 months for the assessment of recurrence irrespective of R0 status. N, number; R0, histologically-confirmed en bloc resection 1 The rates are calculated as a percentage of the total number of tumors operated. 2 Immediate refers to adverse outcomes occurring within 24 hours of the procedure. 3 Delayed refers to adverse outcome occurring 24 hours after the procedure. 4 Average follow-up was~20, 19, and 25 months for assessment of recurrence among tumors with R0, without R0, and irrespective of R0 status respectively (for Asian studies); and 7, 7, and 10 months for assessment of recurrence among tumors with R0, without R0, and irrespective of R0 status respectively (for western studies).
Before the invention of ESD in the late 1990s in Japan, EMR was the most widely used minimally invasive option for noninvasive colorectal tumors in the world and it is still the most widely used in many western countries. Over the years, numerous comparative studies and reviews had shown the superior benefit of ESD in terms of complete resection and tumor recurrence as compared to EMR [4, 8, 10] . In addition, its risk of complication is comparable to other minimally invasive alternative including EMR and laparoscopic assisted colectomy (LAC) [11] . However, given the low risk of malignancy among small tumors (< 20 mm in diameter) in addition to comparable rate of recurrence between EMR and ESD for small tumors, EMR remains a suitable option in this subgroup especially when ESD cannot be performed due to lack of expertise or patient-related factors e. g. weak intestinal wall [10] . Furthermore, ESD is not recommended for invasive cancers with risk of lymph node metastasis. LAC remains the only minimally invasive option in such cases [11] . Our study has several strengths. Notably, a guideline-driven approach ensures that our analysis was systematic and comprehensive. In addition, we made attempt to gather all available data by including all comprehensive abstracts and placing no restriction on language of publication. Our moderately large number of studies enabled us to shed more light on potential sources of heterogeneity in treatment success after ESD, and the comparability of the main findings to those in sensitivity analysis further ensures the robustness of our result. Although similar studies exist in the literature [12 -14] , our study is the largest and most updated. In addition, we provided the most comprehensive reporting of all clinically relevant outcomes while also identifying potential sources of heterogeneity. Limitations of this study should also be considered. First, due to rapidly evolving techniques in ESD procedure, the rates of each outcome may vary slightly by technique and our rates of adverse outcomes might have been over-estimated compared to new technique. There was also a suggestion of increasing rate of treatment success over time, indicating that newer techniques may be associated with higher success rate, although this was not statistically significant. Second, the recurrence rates were assessed after variable follow up between and within study, and since the rate of recurrence is time-dependent, cautious interpretation of average follow-up reported is warranted when applied to individual cases. Third, we could not evaluate for potential heterogeneity of clinical outcomes between mucosal and submucosal tumors as most of the studies involved a mixed population of mucosal and submucosal tumors. Further studies are needed to evaluate these 2 classes of tumors in a head-to-head comparison.
Conclusion
!
In conclusion, colorectal ESD appears safe and effective based on the large and broad body of current medical literature. It compares favorably with other minimally invasive options and warrants consideration as first-line therapy when an expert operator is available. However, the result is not optimal yet given that R0 resection rate is still only 86 % and there is enough room for improvement to achieve rates close to 100 %.
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